Attenuated vaccine

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Retrieved on: 
Tuesday, March 19, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Emory University, Antigen, Streptococcus, International Society, HIV, Risk, Global health, Patient, Cohort, Hospital, Merck & Co., Aes, OPA, Epidemiology, Training school (United States), PCV20, Immunoglobulin G, Attenuated vaccine, MRK, Pediatrics, CDC, Vaccination, PPSV23, Community-acquired pneumonia, Food, FDA, PDUFA, Medicine, Vaccine

V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.

Key Points: 
  • V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116 in all STRIDE studies presented at the meeting.
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Participants were enrolled based on previous pneumococcal vaccination with PPSV23, PCV15, PCV13 (pneumococcal 13-valent conjugate vaccine), PPSV23+PCV13, PCV13+PPSV23 or PCV15+PPSV23, and received either V116, PCV15 or PPSV23.
  • V116 elicited comparable immune responses to the comparator, PCV15+PPSV23, for all 13 shared serotypes and higher immune responses for the eight serotypes covered only by V116.

Global Vaccine Technologies Market Report 2024, Featuring Abbott, Astrazeneca, Bavarian Nordic, Emergent Biosolutions, GSK, Merck, Mitsubishi Tanabe Pharma, Panacea Biotec, Pfizer & Sanofi - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Acquisition, Attenuated vaccine, Immunization, BCG, Physician, Cancer, Influenza, ESG, Government, Allergy, Vaccine, Rotavirus, MMR, Disease, HPV, Infection, Diphtheria, Hepatitis, Research, Human, Pharmaceutical industry

Continuous improvements in vaccine design, delivery technologies and manufacturing will also boost market growth.

Key Points: 
  • Continuous improvements in vaccine design, delivery technologies and manufacturing will also boost market growth.
  • The global vaccine technologies market is segmented in this report by technology, disease, age, and region.
  • It discusses the market determinants, which act as motivating or restraining factors and provides insights to stakeholders and potential entrants.
  • This study looks at research and development (R&D) spending, increasing competition and new technologies, which are giving direction to the market.

Prevent Cancer Foundation awards $380,000 in global innovation grants

Retrieved on: 
Thursday, January 11, 2024
Woman, Incidence, Mother, Global health, Survival, Curriculum, Google Images, Breast cancer, AI, Cancer, Vaccination, Cervical cancer, Games Done Quick, HPV, Diagnosis, Attenuated vaccine, Medical imaging

The 2024 Global Innovation Grants intend to reduce global health disparities by funding novel and impactful projects in cancer prevention, screening and vaccination in low- and middle-income countries.

Key Points: 
  • The 2024 Global Innovation Grants intend to reduce global health disparities by funding novel and impactful projects in cancer prevention, screening and vaccination in low- and middle-income countries.
  • “From training the country’s first breast radiologists in Zambia and testing AI-supported breast cancer diagnosis in Nigeria to implementing novel approaches for addressing cervical cancer in Cameroon and Mexico, the Prevent Cancer Foundation is proud to support the 2024 Global Innovation Grants as we dare to imagine a world where cancer is preventable, detectable and beatable for all.” said Jody Hoyos, CEO of the Prevent Cancer Foundation.
  • These global innovation grants are made possible by Awesome Games Done Quick, an annual livestreamed video game marathon organized by Games Done Quick to raise funds for the Prevent Cancer Foundation.
  • For more information on the Prevent Cancer Foundation’s Global Innovation Grants, visit www.preventcancer.org/programs/our-global-reach/global-grants/ .

MotherToBaby Launches Spanish-Language Digital Health Website to Reach Underserved Latinx Communities in the U.S. & Canada

Retrieved on: 
Wednesday, January 10, 2024
Midwifery, Zolpidem, Research, Government, Pediatrics, Health, Genetics, FREE, Gynaecology, Teratology, Organization, Language, Risk, Public, HRSA, CDC, Pharmacy, Genetic counseling, Pregnancy, OTIS, Heel, COVID-19, HHS, Child, Obstetrics, Unitary state, Nursing, Parent, MPH, Attenuated vaccine, Vaccine, Birth, Birth control

BRENTWOOD, Tenn., Jan. 10, 2024 /PRNewswire-PRWeb/ -- ¿Hablas español? ¡Sí! In time for January's Birth Defects Awareness Month, MotherToBaby is proud to announce the launch of its fully bilingual (English/Spanish) website. It's the first of its kind for housing an extensive bilingual library of fact sheets on everything from alcohol to zolpidem during pregnancy and breastfeeding as well as connecting bilingual experts with parents and healthcare providers.

Key Points: 
  • In time for January's Birth Defects Awareness Month, MotherToBaby is proud to announce the launch of its fully bilingual ( English / Spanish ) website.
  • "No matter what the language they speak is, we want everyone to have access to the best, expert health information possible."
  • The now fully bilingual website is designed to fill the gap in the disparities of health education information for pregnant and breastfeeding individuals who are Spanish-speakers.
  • MotherToBaby wants to improve birth outcomes in the Latinx community by giving improved access to language-appropriate resources to families and health professionals.

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Retrieved on: 
Monday, December 4, 2023
The Lancet, PCV, Death, Vaccine, Disease, Attenuated vaccine, SAN, PCV20, Public, IPD, Safety, Bacteria, Genetically modified bacteria

SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the publication of the results from the VAX-24 Phase 1/2 clinical proof-of-concept study in the journal The Lancet Infectious Diseases. This study evaluated the safety, tolerability and immunogenicity of Vaxcyte’s investigational 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) compared to the current standard-of-care, Prevnar 20® (PCV20), for the prevention of invasive pneumococcal disease (IPD) in healthy adults 18-64 years of age. The study results showed VAX-24 demonstrated a safety and tolerability profile that was comparable to PCV20 at all doses studied, and an immunogenicity profile that met or exceeded established regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2 mcg dose. The Company plans to advance the VAX-24 2.2 mcg dose into a Phase 3 program.

Key Points: 
  • This study evaluated the safety, tolerability and immunogenicity of Vaxcyte’s investigational 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) compared to the current standard-of-care, Prevnar 20® (PCV20), for the prevention of invasive pneumococcal disease (IPD) in healthy adults 18-64 years of age.
  • The Company plans to advance the VAX-24 2.2 mcg dose into a Phase 3 program.
  • “Despite the availability of pneumococcal vaccines, the bacteria associated with IPD continues to be a major driver of deaths as a result of antimicrobial resistance.
  • “We look forward to initiating our Phase 3 pivotal, non-inferiority study, which is designed to further establish the clinical potential of VAX-24, and announcing topline data, which we expect in 2025.”

FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults

Retrieved on: 
Tuesday, December 19, 2023
FDA, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, MSD, CDC, Food, Risk, PDUFA, Vaccine, Streptococcus, Attenuated vaccine, Merck & Co., Safety, MRK, BLA

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new Biologics License Application (BLA) for V116, the company’s investigational 21-valent pneumococcal conjugate vaccine specifically designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.

Key Points: 
  • Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new Biologics License Application (BLA) for V116, the company’s investigational 21-valent pneumococcal conjugate vaccine specifically designed to help prevent invasive pneumococcal disease and pneumococcal pneumonia in adults.
  • The FDA grants priority review to medicines and vaccines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment or prevention of a serious condition.
  • The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action date, of June 17, 2024.
  • “If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed to address the serotypes that cause most adult invasive pneumococcal disease.

Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older

Retrieved on: 
Tuesday, November 28, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, MSD, OPA, Safety, NYSE, Cohort, Merck & Co., Aes, Risk, Immunodeficiency, Patient, Molina Healthcare, GMT (TV programme), Vaccine, 9N, Fungal infection, Leucauge, Streptococcus, 20A, 10A, CDC, Attenuated vaccine, EST, Public, MRK, Pharmaceutical industry, PCV20, V116, Merck

The trial evaluated the immunogenicity, tolerability and safety of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults who had not previously received a pneumococcal vaccine.

Key Points: 
  • The trial evaluated the immunogenicity, tolerability and safety of V116 compared to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults who had not previously received a pneumococcal vaccine.
  • In adults 18 to 49 years of age (Cohort 2), V116 elicited non-inferior immune responses (immunobridged) compared to adults 50 to 64 years of age, as assessed by serotype-specific OPA GMTs 30 days post-vaccination.
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Participants administered V116 and PCV20 who reported at least 1 adverse event (AE) were 61.7% and 67.2%, respectively.

3 Things To Know on World Pneumonia Day

Retrieved on: 
Thursday, November 9, 2023
National Foundation for Infectious Diseases, Streptococcus, Fungal infection, Respiratory failure, Attenuated vaccine, Vaccine, American Lung Association, MD, NFID, HIV, Diabetes, Sickle cell disease, Kidney, Fever, Cough, Chest pain, Vaccination, Disease, Risk, Immune system, COVID-19, Asthma, Chills, Infection, Sepsis, Diagnosis, Death, Pneumonia

In support of World Pneumonia Day on November 12, NFID and the American Lung Association are working to raise awareness about pneumococcal disease and encourage those who are at risk to talk with a healthcare professional about pneumococcal vaccination.

Key Points: 
  • In support of World Pneumonia Day on November 12, NFID and the American Lung Association are working to raise awareness about pneumococcal disease and encourage those who are at risk to talk with a healthcare professional about pneumococcal vaccination.
  • Here are 3 things to know on World Pneumonia Day:
    Anyone can get pneumonia, but some people are at higher risk.
  • "Even healthy adults over 65 years are at increased risk for pneumococcal pneumonia, because the body's immune system naturally weakens with age.
  • "Fortunately, pneumococcal pneumonia vaccines are available to help prevent the disease."

FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents

Retrieved on: 
Friday, October 20, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Survivor, NYSE, Upstate University Hospital, Food, Meningococcal disease, Vaccine, Mortality, MD, Infection, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Development, Senior, CDC, Inc., Attenuated vaccine, IMD, Head, ACIP, Safety, PFE, Patient, Hospital, Death, Pfizer

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved PENBRAYA™ (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides coverage against the most common serogroups causing meningococcal disease in adolescents and young adults 10 through 25 years of age.
  • “Today marks an important step forward in the prevention of meningococcal disease in the U.S.
  • The Phase 3 trial (NCT04440163) evaluated more than 2,400 patients from the U.S. and Europe.
  • The CDC Advisory Committee on Immunization Practices (ACIP) will meet on October 25, 2023, to discuss recommendations for the appropriate use of PENBRAYA in adolescents and young adults.

RNA Therapeutics Market Poised for Explosive Growth: Estimated Worth Exceeds $1.1 Billion by 2035, with a Remarkable 50% CAGR from 2026-2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Transfer, Gene expression, Vaccine, Infection, Investment, Vertex Pharmaceuticals, Engineering, Sarcoidosis, RNA, USD, Therapy, Safety, SaRNA, Cystic fibrosis, Attenuated vaccine, Erna, Duchenne muscular dystrophy, Recode, Messenger, Circular RNA, Small RNA, China-ASEAN Investment Cooperation Fund, RNA therapeutics, Research, Pharmaceutical industry

The "RNA Therapeutics Market and RNA Vaccines Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "RNA Therapeutics Market and RNA Vaccines Market" report has been added to ResearchAndMarkets.com's offering.
  • Next Generation RNA Therapeutics and Vaccines: The market is witnessing the development of next-generation RNA therapeutics and vaccines that target diseases previously considered undruggable.
  • These include modalities such as circular RNA (circRNA), endless RNA (eRNA), self-activating RNA (sacRNA), self-amplifying RNA (saRNA), self-amplifying mRNA (samRNA), replicating RNA (repRNA), and transfer RNA (tRNA).
  • Investment and Funding: The market has attracted substantial investments, with over $2.9 billion raised or invested in RNA therapeutics and RNA vaccines development since 2019.